ライフサイエンスコーパス: mesenchymal stromal cell

1 surround a single HSPC attached to a single mesenchymal stromal cell.

2 further improve the therapeutic potential of mesenchymal stromal cells.

3 sing the patient's own immune or bone marrow mesenchymal stromal cells.

4 A, which expressed surface markers common to mesenchymal stromal cells.

5 by Mcl-1 or by interactions with bone marrow mesenchymal stromal cells.

6 h the recipient's respiratory epithelium and mesenchymal stromal cells.

7 y in promoting osteogenic differentiation of mesenchymal stromal cells.

8 ose-derived stromal cells and marrow-derived mesenchymal stromal cells.

9 patients as well as in vitro-cultured human mesenchymal stromal cells.

10 d defects in skull, articular cartilage, and mesenchymal stromal cells.

11 expressed in cells and tissues arising from mesenchymal stromal cells.

12 ng cord blood that was expanded ex vivo with mesenchymal stromal cells.

13 panded ex vivo in cocultures with allogeneic mesenchymal stromal cells.

14 l progenitor colony cells were surrounded by mesenchymal stromal cells.

15 through donor-derived mononuclear cells and mesenchymal stromal cells.

16 ates persistent expression into adulthood in mesenchymal stromal cells.

17 es, and an immunophenotype characteristic of mesenchymal stromal cells.

18 mors contained a mixture of cancer cells and mesenchymal stromal cells.

19 cts of gene expression by tumor-infiltrating mesenchymal stromal cells.

20 ile reducing passive stiffness compared with mesenchymal stromal cells.

21 ling detrimental cross-talk with bone marrow mesenchymal stromal cells.

22 duces collagen deposition in the bone marrow mesenchymal stromal cells.

23 or mitochondria-rich fraction isolated from mesenchymal stromal cells (3 x 106) IV.

24 Endomyocardial injections of iron-labeled mesenchymal stromal cells admixed with tissue dye were p

25 sibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of

26 Adipose tissue contains adipose-derived mesenchymal stromal cells (ADSCs) that have regenerative

27 agen VII expressed by intradermally injected mesenchymal stromal cells also exhibited a similar half-

28 Live imaging showed that mesenchymal stromal cells anchor HSPCs and orient their

29 erse relationship between a subpopulation of mesenchymal stromal cells and cancer cells in the bone m

30 ation inhibits the regenerative potential of mesenchymal stromal cells and derived extracellular vesi

31 Whereas wild-type mesenchymal stromal cells and derived vesicles administe

32 after injury were restored by treatment with mesenchymal stromal cells and derived vesicles but not w

33 gineered by inducing chondrogenesis of human mesenchymal stromal cells and devitalized by the impleme

34 The niche is perivascular, created partly by mesenchymal stromal cells and endothelial cells and ofte

35 y causes an immediate, transient response of mesenchymal stromal cells and endothelial cells followed

36 ramedullary bone and bone marrow using human mesenchymal stromal cells and endothelial colony-forming

37 rm repopulating of hematopoietic stem cells, mesenchymal stromal cells and endothelial progenitors.

38 ions reverted after treatment with wild-type mesenchymal stromal cells and extracellular vesicles but

39 In conclusion, microRNA depletion in mesenchymal stromal cells and extracellular vesicles sig

40 Mesenchymal stromal cells and liver fibrosis: a complica

41 The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the

42 ncapsulation in microporous hydrogels, human mesenchymal stromal cells and osteoblasts spread rapidly

43 ne marrow myofibroblasts derive from Gli1(+) mesenchymal stromal cells and that a Gli inhibitor targe

44 Of those, mesenchymal stromal cells and, to a lesser extent, regul

45 on of adult human hMSCs (bone marrow-derived mesenchymal stromal cells) and cKit(+) cardiac cells.

46 t nonmalignant peripheral blood lymphocytes, mesenchymal stromal cells, and CD34-positive hematopoiet

47 signalling, adhesion to primary bone-marrow mesenchymal stromal cells, and proliferation of primary

48 plantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effect

49 Mesenchymal stromal cells are being investigated as a ce

50 nvestigate the paracrine mechanisms by which mesenchymal stromal cells are protective in hypoxic pulm

51 Adventitial fibroblasts (AFs), a subtype of mesenchymal stromal cell, are the dominant constituents

52 re the safety, tolerability, and efficacy of mesenchymal stromal cell-based therapy in pilot clinical

53 In vitro studies have shown that bone marrow mesenchymal stromal cells (BM-MSC) protect AML blasts fr

54 Bone marrow-derived mesenchymal stromal cells (BM-MSCs) in culture are deriv

55 ct of local injection of bone marrow-derived mesenchymal stromal cells (BM-MSCs) or adipose tissue-de

56 BM mesenchymal stromal cells (BM-MSCs) support multiple mye

57 ve this challenge, human bone marrow-derived mesenchymal stromal cells (BM-MSCs) were used to efficie

58 comparable to osteogenic cells derived from mesenchymal stromal cells (BM-MSCs).

59 tosis by their interactions with bone marrow mesenchymal stromal cells (BM-MSCs).

60 stem cells (iHepSCs) and bone marrow derived mesenchymal stromal cells (BMSCs) were used to CBTs for

61 Bone marrow-derived mesenchymal stromal cells (BMSCs), commonly used to desc

62 in a loss of therapeutic benefit bestowed on mesenchymal stromal cells by carbon monoxide.

63 -inducible factor 1alpha was knocked down in mesenchymal stromal cells by lentiviral transfer of shor

64 ave shown convincingly in rodent models that mesenchymal stromal cells can prolong solid organ graft

65 Ms) as the target of mouse and human cardiac mesenchymal stromal cells (cMSC) with progenitor-like fe

66 te+/-SE, 0.01+/-0.002; P<0.001), multipotent mesenchymal stromal cell colony maximum (estimate+/-SE,

67 mate+/-SE, 0.01+/-0.002; P=0.002) in BM, and mesenchymal stromal cell colony maximum in PB (estimate+

68 We fractionated mouse mesenchymal stromal cell-conditioned media to identify t

69 Mesenchymal stromal cells, mesenchymal stromal cells-conditioned with carbon monoxi

70 Splenic erythroid progenitor cells and mesenchymal stromal cells contribute directly and indire

71 n in BM stromal elements, including CD146(+) mesenchymal stromal cells, correlates with the degree of

72 We showed that mesenchymal stromal cells, cortical bone stem cells, and

73 Mesenchymal stromal cells create and maintain specialize

74 After intravenous infusion of mesenchymal stromal cells (CYP-001 derived from a clone

75 We generated mesenchymal stromal cells depleted of Drosha to alter mi

76 Furthermore, we introduce a mesenchymal stromal cell derived from human olfactory ti

77 Intravenous delivery of mesenchymal stromal cell-derived exosomes (MEX) inhibite

78 Mesenchymal stromal cells did not alter clinical score o

79 Endothelial and mesenchymal stromal cells (ECs/MSCs) are crucial compone

80 lving lipid mediators contribute to improved mesenchymal stromal cell efficacy when exposed to carbon

81 Engraftment of engineered mesenchymal stromal cells (eMSCs) together with CD34(+)

82 uine endometrial epithelial cells (eECs) and mesenchymal stromal cells (eMSCs).

83 in situ differentiation of human BM-derived mesenchymal stromal cells, enables the robust engraftmen

84 We find that mesenchymal stromal cells engineered to express membrane

85 in vivo selection of cytokines that improve mesenchymal stromal cell engraftment into the heart both

86 he batch transduction of bone marrow-derived mesenchymal stromal cells ex vivo, followed by intramyoc

87 Mesenchymal stromal cells exposed to carbon monoxide, wi

88 separation efficacy of >98% in pre-purified mesenchymal stromal cells, extracted from human dental p

89 Bone marrow-derived mesenchymal stromal cells from hypomorphic mice, as well

90 Multipotent mesenchymal stromal cells from the bone marrow ameliorat

91 ng lipid mediators, and their importance for mesenchymal stromal cells function using gene silencing.

92 Adipose mesenchymal stromal cells, haematopoietic stem cells and

93 modulatory efficacy of regulatory T cells or mesenchymal stromal cells has been demonstrated in vitro

94 The differentiation of mesenchymal stromal cells has been shown to be affected

95 Mesenchymal stromal cells have emerged as potential cand

96 Mesenchymal stromal cells have emerged as powerful modul

97 In this study, human bone marrow-derived mesenchymal stromal cell (hMSCs) was used as a viral rep

98 Human mesenchymal stromal cells (hMSCs) are a promising source

99 Human multipotent mesenchymal stromal cells (hMSCs) produce tumor necrosis

100 Scaffolds coated with human mesenchymal stromal cells (hMSCs) proved to be superior

101 Adipocytes differentiate from multipotent mesenchymal stromal cells (hMSCs) through adipogenesis,

102 Human mesenchymal stromal cells (hMSCs) were injected into the

103 ation of bone forming osteoblasts from human mesenchymal stromal cells (hMSCs).

104 acts directly on Leptin-Receptor-expressing mesenchymal stromal cells in adult bone marrow to influe

105 s significantly augmented in macrophages and mesenchymal stromal cells in inflamed human pulp tissues

106 and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal

107 Furthermore, BM mesenchymal stromal cells in patients with DADA2 exhibit

108 g regulates adipogenesis and osteogenesis by mesenchymal stromal cells in the bone marrow in response

109 ation toward CXCL12 and reducing adhesion to mesenchymal stromal cells in vitro We also found that HI

110 of mesenchymal stem cells (MSCs, also called mesenchymal stromal cells) in endogenous repair and cell

111 logeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticostero

112 how that asporin regulates key properties of mesenchymal stromal cells, including self-renewal and mu

113 ing Dab2-deficient embryonic fibroblasts and mesenchymal stromal cells indicated that Dab2 promoted a

114 e nuclear and cellular morphologies of human mesenchymal stromal cells induced by micropillar pattern

115 MEX produced by human umbilical cord mesenchymal stromal cells inhibited STAT3 signaling in i

116 planting ceramic scaffolds coated with human mesenchymal stromal cells into immune-deficient mice, we

117 brain injured mice receiving human amniotic mesenchymal stromal cells intravenously or intracerebrov

118 hours after surgery, mice were treated with mesenchymal stromal cells IV (1 x 10 cells in 0.05 mL of

119 ate alpha7 nicotinic receptor in bone marrow mesenchymal stromal cells leading to increased CXCL12 ex

120 Coculture with mesenchymal stromal cells led to an expansion of total n

121 Encapsulated mesenchymal stromal cells locally contract low fiber den

122 ologic function in human adult lung-resident mesenchymal stromal cells (LR-MSCs) remain to be elucida

123 upregulated upon damage and is expressed in mesenchymal stromal cells, macrophages, and Paneth cells

124 In addition, mesenchymal stromal cells may participate in several ste

125 Mesenchymal stromal cells, mesenchymal stromal cells-con

126 Mesenchymal stromal cells mitigated these cognitive and

127 ion were assessed in bone marrow multipotent mesenchymal stromal cell models.

128 about the potentially unfavorable effects of mesenchymal stromal cell (MSC) activation on the heart.

129 Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated

130 stretch have been investigated for inducing mesenchymal stromal cell (MSC) differentiation towards t

131 identify asporin (ASPN) as a novel, secreted mesenchymal stromal cell (MSC) factor in the tumor micro

132 Human mesenchymal stromal cell (MSC) lines can vary significan

133 We investigated and modeled the mesenchymal stromal cell (MSC) niche in adult acute lymp

134 But the mechanisms underlying OA-mediated mesenchymal stromal cell (MSC) osteogenic differentiatio

135 to isolate a quiescent and undifferentiated mesenchymal stromal cell (MSC) population from the bone

136 A mesenchymal stromal cell (MSC) specific CreERT2 line was

137 Original techniques based on mesenchymal stromal cell (MSC) therapy are emerging with

138 Mesenchymal stromal cell (MSC) therapy demands the atten

139 Clinical trials investigating mesenchymal stromal cell (MSC) therapy for bronchopulmon

140 Rationale: Mesenchymal stromal cell (MSC) therapy is a promising in

141 Autologous mesenchymal stromal cell (MSC) treatments have shown fea

142 ll apoptosis, and could overcome bone marrow mesenchymal stromal cell (MSC)-induced chemoresistance.

143 ion (DR) in both ex vivo bone marrow-derived mesenchymal stromal cells (MSC) and in vitro 3T3-L1 prea

144 Multipotent mesenchymal stromal cells (MSC) are a possible source of

145 Mesenchymal stromal cells (MSC) are potential renal ther

146 Mesenchymal stromal cells (MSC) are used extensively in

147 The ability to use mesenchymal stromal cells (MSC) directly out of cryostor

148 contributions to primary myelofibrosis from mesenchymal stromal cells (MSC) have been suggested by m

149 premetastatic niche by examining the role of mesenchymal stromal cells (MSC) in cancer cell homing.

150 umbilical vein endothelial cell (HUVEC) and mesenchymal stromal cells (MSC) onto the decellularized

151 ure of leukemia cells to bone marrow-derived mesenchymal stromal cells (MSC) promotes accumulation of

152 Bone marrow (BM) mesenchymal stromal cells (MSC) provide microenvironment

153 posure of cultured mouse bone marrow-derived mesenchymal stromal cells (MSC) to hypoxia or an adenovi

154 Autologous mesenchymal stromal cells (MSC) treatments have shown fe

155 We report that BM mesenchymal stromal cells (MSC) undergo massive damage t

156 endothelial precursors, abundantly available mesenchymal stromal cells (MSC) were reprogrammed into i

157 (CAF) have been suggested to originate from mesenchymal stromal cells (MSC), but their relationship

158 ase IL1beta, which induces PGE2 synthesis in mesenchymal stromal cells (MSC), in turn activating beta

159 ytic leukemic (CLL) cells and marrow-derived mesenchymal stromal cells (MSCs) activates both cell typ

160 These enzymes were detected both in LN mesenchymal stromal cells (MSCs) and in Reed-Sternberg (

161 es osteogenic differentiation of multipotent mesenchymal stromal cells (MSCs) and lineage progression

162 Adherent progenitor cells, including mesenchymal stromal cells (MSCs) and multipotent adult p

163 Mesenchymal stromal cells (MSCs) are a major component o

164 Mesenchymal stromal cells (MSCs) are a promising candida

165 Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment op

166 vironments that modulate fate commitments of mesenchymal stromal cells (MSCs) are composed of chemica

167 As mesenchymal stromal cells (MSCs) are continuously expose

168 Activation and migration of endogenous mesenchymal stromal cells (MSCs) are critical for bone r

169 Multipotent mesenchymal stromal cells (MSCs) are found in an increas

170 Mesenchymal stromal cells (MSCs) are heterogeneous and p

171 Mesenchymal stromal cells (MSCs) are immunomodulatory an

172 Nestin-expressing (Nestin(+)) mesenchymal stromal cells (MSCs) are important in the pe

173 Mesenchymal stromal cells (MSCs) are inherently tumor ho

174 Mesenchymal stromal cells (MSCs) are multipotent cells w

175 Mesenchymal stromal cells (MSCs) are one of major compon

176 RATIONALE: Mesenchymal stromal cells (MSCs) are promising therapeut

177 Multipotent mesenchymal stromal cells (MSCs) are rare cells resident

178 ing in two murine models of BMF that Gli1(+) mesenchymal stromal cells (MSCs) are recruited from the

179 Multipotent mesenchymal stromal cells (MSCs) are required for skelet

180 Mesenchymal stromal cells (MSCs) are strongly immunosupp

181 Here we describe how mesenchymal stromal cells (MSCs) can be used to systemic

182 Mesenchymal stromal cells (MSCs) constitute, based on an

183 ed with long-term passaged (P10) aging human mesenchymal stromal cells (MSCs) could be used for bone

184 n iTreg co-cultured with bone marrow-derived mesenchymal stromal cells (MSCs) during short-term ex vi

185 y demonstrated that coculture of islets with mesenchymal stromal cells (MSCs) enhanced islet insulin

186 ) cells in the presence of bone marrow-human mesenchymal stromal cells (MSCs) enhanced the production

187 Mesenchymal stromal cells (MSCs) for basic research and

188 in preparation for a first-in-human trial of mesenchymal stromal cells (MSCs) for septic shock, we ap

189 n a rapid expansion in clinical trials using mesenchymal stromal cells (MSCs) from a variety of tissu

190 d the adipogenic potential of marrow-derived mesenchymal stromal cells (MSCs) from mice with decrease

191 the BM extracellular fluid were elevated and mesenchymal stromal cells (MSCs) had a reduced capacity

192 Use of mesenchymal stromal cells (MSCs) has become standard pra

193 The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been investigated i

194 the past decade, the clinical application of mesenchymal stromal cells (MSCs) has generated growing e

195 Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has shown benefits in p

196 f the identity and physiological function of mesenchymal stromal cells (MSCs) have been hampered by a

197 Bone marrow mesenchymal stromal cells (MSCs) have been studied for d

198 Mesenchymal stromal cells (MSCs) have demonstrated poten

199 Therapeutic uses of mesenchymal stromal cells (MSCs) have emerged over the p

200 Mesenchymal stromal cells (MSCs) have enormous potential

201 Mesenchymal stromal cells (MSCs) have great potential to

202 Mesenchymal stromal cells (MSCs) have immune modulatory

203 Mesenchymal stromal cells (MSCs) have protolerogenic eff

204 n that drives lung failure, while unmodified mesenchymal stromal cells (MSCs) have shown only modest

205 Mesenchymal stromal cells (MSCs) have the potential to t

206 nt strategies have pursued the idea of using mesenchymal stromal cells (MSCs) in combination with ost

207 and safety of osteoarthritis treatment with mesenchymal stromal cells (MSCs) in humans and to obtain

208 strate expression exclusively in multipotent mesenchymal stromal cells (MSCs) in the bone marrow of t

209 eviously identified a resident population of mesenchymal stromal cells (MSCs) in the terminal airways

210 ctor [SCF], ThPO, and IL-6) from bone marrow mesenchymal stromal cells (MSCs) in vitro.

211 Human bone marrow-derived mesenchymal stromal cells (MSCs) inhibit proliferation o

212 steering the chondrogenic differentiation of mesenchymal stromal cells (MSCs) into either permanent c

213 val, growth, and myogenic differentiation of mesenchymal stromal cells (MSCs) isolated from adipose o

214 In previous studies we have shown that mesenchymal stromal cells (MSCs) isolated from bone marr

215 one marrow (BMT) as well as ex vivo-expanded mesenchymal stromal cells (MSCs) leads to striking clini

216 ell viability and homogenous distribution of mesenchymal stromal cells (MSCs) observed throughout pri

217 the hypothesis that the favorable effects of mesenchymal stromal cells (MSCs) on infarct repair are m

218 ated when the CLL cells were cocultured with mesenchymal stromal cells (MSCs) or hyaluronic acid or w

219 Multipotent mesenchymal stromal cells (MSCs) possess reparative and

220 Mesenchymal stromal cells (MSCs) present in the bone mar

221 Topically applied mesenchymal stromal cells (MSCs) provide a novel treatme

222 e show that targeted deletion of Cxcl12 from mesenchymal stromal cells (MSCs) reduces normal HSC numb

223 ates to bone marrow, where interactions with mesenchymal stromal cells (MSCs) shape disease trajector

224 Coculture with human BM mesenchymal stromal cells (MSCs) significantly inhibited

225 In addition, mesenchymal stromal cells (MSCs) support in vitro FL B-c

226 Mesenchymal stromal cells (MSCs) tend to infiltrate into

227 e marrow (BM) niche contains a population of mesenchymal stromal cells (MSCs) that provide physical s

228 Bone marrow mesenchymal stromal cells (MSCs) tightly regulate hemato

229 Activated T cells polarize mesenchymal stromal cells (MSCs) to a proinflammatory Th

230 ernative approaches aim to infuse allogeneic mesenchymal stromal cells (MSCs) to provide a more gener

231 local administration of bone marrow-derived mesenchymal stromal cells (MSCs) to these patients from

232 eutically relevant quantities of multipotent mesenchymal stromal cells (MSCs) via in vitro culture is

233 and insulin-like growth factor 1 (IGF1) from mesenchymal stromal cells (MSCs) was predicted to have t

234 luid (SF) in the knee serve as reservoirs of mesenchymal stromal cells (MSCs) with potential therapeu

235 Prior studies that have transplanted mesenchymal stromal cells (MSCs) without co-administrati

236 CSF) secreted from human bone marrow-derived mesenchymal stromal cells (MSCs), all of which also cont

237 one marrow (BM) affects local cells, such as mesenchymal stromal cells (MSCs), leading to osteolysis

238 Here, we show that Gli1(+) mesenchymal stromal cells (MSCs), previously shown to co

239 emia (CLL) cells interact in the marrow with mesenchymal stromal cells (MSCs), which can enhance CLL-

240 osteogenic properties of bone marrow-derived mesenchymal stromal cells (MSCs)-seeded bone micropartic

241 lly on interleukin (IL)-33 produced by local mesenchymal stromal cells (mSCs).

242 iated by cell therapy with human bone marrow mesenchymal stromal cells (MSCs).

243 three-dimensional (3D) condensates of human mesenchymal stromal cells (MSCs).

244 BCP-ALL) cells use TNTs to signal to primary mesenchymal stromal cells (MSCs).

245 ociated cells, including dendritic cells and mesenchymal stromal cells (MSCs).

246 ngiogenic and immunomodulatory properties to mesenchymal stromal cells (MSCs).

247 to as mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs).

248 ptin receptor (Lepr)-expressing perivascular mesenchymal stromal cells (MSCs).

249 rent cell types including vascular cells and mesenchymal stromal cells (MSCs).

250 dels comprising AML cells, normal HSPCs, and mesenchymal stromal cells (MSCs).

251 ruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs).

252 ytes were treated with exosomes derived from mesenchymal stromal cells (MSCs).

253 med by in situ differentiation of BM-derived mesenchymal stromal cells (MSCs).

254 ant changes in the abundance of perivascular mesenchymal stromal cells (MSCs)/osteoprogenitors and os

255 Although multipotent mesenchymal stromal cells (MSCs, also termed 'mesenchyma

256 ly administering vessel-forming cells (human mesenchymal stromal cells [MSCs] and endothelial colony-

257 = 40); arm 2: umbilical cord tissue-derived mesenchymal stromal cells (n = 120), CSI (n = 40); arm 3

258 is cartilage contains chondrocytes (OAC) and mesenchymal stromal cells (OA-MSC).

259 deprivation and treated with human amniotic mesenchymal stromal cells or conditioned medium showed c

260 lled cortical impact received human amniotic mesenchymal stromal cells or phosphate-buffered saline i

261 deprivation were treated with human amniotic mesenchymal stromal cells or with their secretome (condi

262 ound that by inducing TGF-beta activation on mesenchymal stromal cells (pericytes), Amphiregulin indu

263 ndent phenotypic changes of nonhematopoietic/mesenchymal stromal cells play a key role in TD humoral

264 -gestation chorionic villus-derived placenta mesenchymal stromal cells (PMSCs) as a potential treatme

265 Upon i.v. injection of bone marrow mesenchymal stromal cells, postischemic functional renal

266 tracellular vesicles have been implicated in mesenchymal stromal cell-promoted recovery of AKI.

267 originate from BM, or of healthy BM-derived mesenchymal stromal cells, protected hemophilia A mice f

268 h lipopolysaccharide, conditioned media from mesenchymal stromal cells reduced astrogliosis, interleu

269 Neuroprotective effect of placenta-derived mesenchymal stromal cells: role of exosomes.

270 Human amniotic mesenchymal stromal cell-secreted factors protect the br

271 Seeded allogeneic mesenchymal stromal cells spontaneously differentiate (p

272 arrow (BM) fibrosis thought to be induced by mesenchymal stromal cells stimulated by overproduced gro

273 rved between the amount of FSTL1 produced by mesenchymal stromal cells, stromal ST2 cells, and monocy

274 A growing body of evidence demonstrates that mesenchymal stromal cells, such as stromal fibroblasts,

275 eview the available data on culture-expanded mesenchymal stromal cells tested in renal transplantatio

276 In this study, we investigate whether mesenchymal stromal cells that constitute a supportive m

277 ous assessment of the safety and efficacy of mesenchymal stromal cell therapies to allow the translat

278 have produced promising results for HSCT and mesenchymal stromal cell therapy as alternatives to syst

279 For patients with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally,

280 poietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for

281 Early clinical trials of mesenchymal stromal cell therapy have shown promising re

282 skin, and suggest an approach for improving mesenchymal stromal cell therapy in scleroderma and othe

283 te, no study has investigated the effects of mesenchymal stromal cell therapy on the blood-brain barr

284 In mice who survived experimental sepsis, mesenchymal stromal cell therapy protected blood-brain b

285 Ps) are metabolically coupled to bone marrow mesenchymal stromal cells through mitochondrial transfer

286 preconditioning with carbon monoxide allowed mesenchymal stromal cells to be administered later after

287 e osteoblast precursor cells and rat primary mesenchymal stromal cells to low-dose PDT.

288 dicating that the exposure of human amniotic mesenchymal stromal cells to the injured tissue is not n

289 Intracardiac injection of mesenchymal stromal cells transiently preconditioned wit

290 Mesenchymal stromal cell transplantation inhibits lung i

291 mmunocytes and, importantly, subtypes of VAT mesenchymal stromal cells (VmSCs) that are either immuno

292 Engraftment of cardiotrophin-1-treated mesenchymal stromal cells was consequent to signal trans

293 Carbon monoxide preconditioned mesenchymal stromal cells were also able to alleviate or

294 Mesenchymal stromal cells were also assessed for their a

295 y contrast, donor BM-derived mononuclear and mesenchymal stromal cells were more abundant and express

296 roinflammatory cytokines in BM-derived human mesenchymal stromal cells, which are part of the hematop

297 trated that IL11 acts on bone-marrow-derived mesenchymal stromal cells, which induce pro-tumorigenic

298 We hypothesized that preconditioning of mesenchymal stromal cells with carbon monoxide ex vivo w

299 We conclude that harnessing local mesenchymal stromal cells with FGF9 can differentiate th

300 , and activation of EphA3(+)/CD90(+)/Sca1(+) mesenchymal/stromal cells with an EphA3 agonist leads to